SDG 3: Good Health & Well-being | SDG 9: Industry, Innovation & Infrastructure
Institutions: Ministry of Science & Technology | Government of Uttar Pradesh
On 30 September 2025, the Government announced that India’s pharma exports, currently ~US $27.8 billion, are projected to exceed US $30 billion by year-end. India’s domestic pharma market is now valued at US $60 billion, with plans to more than double it to US $130 billion by 2030.
To accelerate growth in biotech, pharma, and MedTech, the Department of Biotechnology (DBT) signed a MoU with Uttar Pradesh, involving BIRAC and UPPPC. The pact aims to strengthen innovation, entrepreneurship, skills, state–centre collaboration, and MSME-industry linkages. Currently, India has ~800 medical device manufacturers, and the MedTech sector is growing at 15-20% annually. The DBT–UP partnership will scale biotech/MedTech infrastructure-including Biotech Park (Lucknow), MedTech Park (Greater Noida), and Bulk Drug & Pharma Park (Lalitpur).
This move strengthens India’s “Make in India – MedTech / Pharma” push. The pact aligns with national incentives (PLI, biotech mission) and underscores that state-level ecosystems can catalyse global health technology competitiveness.
What is BIRAC? → The Biotechnology Industry Research Assistance Council, a DBT agency, supports biotech startups, translational research, and innovation.
What is UPPPC? → The Uttar Pradesh Pharma & Pharma Park Corporation (UPPPC) is a state-level agency under the Government of Uttar Pradesh, tasked with developing bulk drug parks, medical device parks, and pharma clusters. It manages infrastructure, incentives, and partnerships to strengthen UP’s role as a pharma–MedTech hub.
Relevant Question for Policy Stakeholders:
How can India ensure that rapid growth in pharma and MedTech clusters also translates into affordable healthcare access and global competitiveness, rather than just export gains?
Follow the full news here: PIB Release